title: Similar efficacy of ciclesonide versus prednisolone to treat asthma worsening after steroid tapering.
abstract: BACKGROUND
  Oral corticosteroids effectively treat asthma exacerbations but are associated with well-described side effects.
  
  
  OBJECTIVE
  This study compared the efficacy and safety of a high dose of an inhaled corticosteroid with oral prednisolone in patients with worsening of their asthma after medication withdrawal.
  
  
  METHODS
  Patients tapered off their inhaled corticosteroids until they reached predefined criteria of "worsening asthma". Randomized patients (n=130) were treated double blind with either ciclesonide 800mug twice daily (starting with 800mug hourly for 3h after randomization) or prednisolone 40mg once daily for 2 weeks. Spirometry, daily asthma symptoms, morning and evening peak expiratory flow and blood parameters were assessed in all, methacholine challenge and inflammatory measures were determined in induced sputum in a subset of patients.
  
  
  RESULTS
  Ciclesonide was as effective as prednisolone in improving forced expiratory flow in 1s, morning peak expiratory flow and symptoms, the latter improving more rapidly with ciclesonide. No differences were found in methacholine responsiveness or inflammatory measures in sputum or blood. Ciclesonide caused significantly less reduction in morning plasma cortisol levels (p<0.0001).
  
  
  CONCLUSIONS
  This study shows that inhaled ciclesonide (800mug twice daily) has comparable efficacy to oral prednisolone (40mg once daily) to regain asthma control in patients with asthma worsening. The more rapid onset and smaller effect on cortisol suppression suggest a better safety profile of ciclesonide.
authors.affiliation: Department of Pulmonology, University Medical Center Groningen, Groningen, The Netherlands. m.van.den.berge@home.nl
authors.forename: M
authors.initials: M
authors.lastname: van den Berge
authors.forename: S H
authors.initials: SH
authors.lastname: Arshad
authors.forename: P W
authors.initials: PW
authors.lastname: Ind
authors.forename: H
authors.initials: H
authors.lastname: Magnussen
authors.forename: E
authors.initials: E
authors.lastname: Hamelmann
authors.forename: F
authors.initials: F
authors.lastname: Kanniess
authors.forename: D S
authors.initials: DS
authors.lastname: Postma
mesh_terms: D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001985:Bronchial Provocation Tests; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate / Q000187:drug effects / Q000502:physiology; D011239:Prednisolone / Q000627:therapeutic use*; D011282:Pregnenediones / Q000627:therapeutic use*; D013183:Sputum
chemical_list: D018927:Anti-Asthmatic Agents; D011282:Pregnenediones; D011239:Prednisolone; C120481:ciclesonide; D006854:Hydrocortisone